ALMS · Alumis Inc.
AI read · Neutral
The AI's read
The psoriasis program appears closer to an FDA filing: Alumis says it remains on track to submit an application in the fourth quarter of 2026, with lasting improvements in its studies. But its lupus study missed its main and other goals across all participants. Strong results in a subgroup do not erase that miss. Taken together, the updates point in different directions.